Gyre Therapeutics 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934For the quarterly period ended June 30, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period fromtoCommission file number: 000-51173 Gyre Therapeutics, Inc.(Exact Name of Registrant as Specified in its Charter) 56-2020050(I.R.S. EmployerIdentification No.) Delaware(State or Other Jurisdiction ofIncorporation or Organization) 12730 High Bluff Drive Suite 250San Diego, California(Address of Principal Executive Offices) 92130(Zip Code) (858) 284-0115(Registrant’s Telephone Number, Including Area Code) Securities registered or to be registered pursuant to Section 12(b) of the Act. Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, par value $0.001 pershareGYREThe NasdaqCapital Market Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”,“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act: Large accelerated filer☐Non-accelerated filer☐Emerging growth company☐ Accelerated filer☒Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of August 01, 2026, the number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was111,509,849, which includes 5,476,086 shares of common stock issued in the name of the registrant to a stock plan administrator ofthe registrant (see Note 8 —Stockholders’ Equity). GYRE THERAPEUTICS, INC.TABLE OF CONTENTS PART I. FINANCIAL INFORMATION Item 1.Financial Statements:2Unaudited Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 20252Unaudited Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income for the threeand six months ended June 30, 2026 and 20253Unaudited Condensed Consolidated Statements of Equity for the three and six months ended June 30, 2026and 20254Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and20256Notes to the Unaudited Condensed Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations41Item 3.Quantitative and Qualitative Disclosures About Market Risk56Item 4.Controls and Procedures56PART II. OTHER INFORMATION57Item 1.Legal Proceedings57Item 1A.Risk Factors57Item 2.Unregistered Sales of Equity Securities and Use of Proceeds57Item 3.Defaults Upon Senior Securities58Item 4.Mine Safety Disclosures58Item 5.Other Information58Item 6.Exhibits59Exhibit Index59Signatures62 Gyre Therapeutics, Inc.Condensed Consolidated Balance Sheets(In thousands, except share and per share amounts)(Unaudited) Gyre Therapeutics, Inc.Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income(In thousands, except share and per share amounts)(Unaudited) Gyre Therapeutics, Inc.Condensed Consolidated Statements of Equity(In thousands, except share amounts)(Unaudited) Gyre Therapeutics, Inc.Condensed Consolidated Statements of Equity(In thousands, except share amounts)(Unaudited) The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Gyre Therapeutics, Inc.Condensed Consolidated Statements of Cash Flows(In thousands)(Unaudited) Operating ActivitiesNet (loss) income Gyre Therapeutics, Inc.Notes to Condensed Consolidated Financial Statements (Unaudited) 1.Organization and Basis of Presentation The Company Gyre Therapeutics, Inc. (the “Company” or “Gyre”), formerly known as Catalyst Biosciences, Inc. (“Catalyst”), is a commercial-stage biopharmaceutical company originally incorporated in Delaware on March 7, 1997 under the name Targacept, Inc. As of June 30, 2026, the Compa